Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.65 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.62 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | UBE2M | P61081 | 1/20 | 0.59 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 1/20 | 0.57 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402061 | 0.88 | SIGMAR1 (0.68) | SIGMAR1MCHR1SLC6A12TMEM97DRD3 | |
| SCHEMBL18658336 | 0.85 | SIGMAR1 (0.71) | SIGMAR1MCHR1SLC6A12TMEM97UBE2M | |
| SCHEMBL1920767 | 0.81 | SIGMAR1 (0.55) | SIGMAR1PRKAA2MCHR1SLC6A12TMEM97 | |
| SCHEMBL4390012 | 0.80 | DRD4 (0.65) | SIGMAR1MCHR1TEAD1 | |
| SCHEMBL6865672 | 0.80 | DRD4 (0.65) | SIGMAR1MCHR1TEAD1 | |
| SCHEMBL3351581 | 0.80 | SIGMAR1 (0.60) | SIGMAR1PRKAA2MCHR1SLC6A12TMEM97 | |
| SCHEMBL3873002 | 0.79 | OPRK1 (0.58) | CCR3DRD3 | |
| SCHEMBL3873003 | 0.79 | OPRK1 (0.58) | CCR3DRD3 | |
| SCHEMBL5862050 | 0.79 | SIGMAR1 (1.00) | SIGMAR1CCR3 | |
| SCHEMBL8037825 | 0.79 | SIGMAR1 (1.00) | SIGMAR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2017049295-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | SIGMAR1 3671/4885PRKAA2 1766/4885MCHR1 3162/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | SIGMAR1 3671/4885PRKAA2 1766/4885MCHR1 3162/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | SIGMAR1 3671/4885PRKAA2 1766/4885MCHR1 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.